Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRG003 + tislelizumab + capecitabine
- Development stage
- Unknown
- Lead developer
- Lepu Biopharma
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
MRG003 + tislelizumab + capecitabine is a combination therapy regimen being evaluated for the treatment of locally recurrent nasopharyngeal carcinoma. The regimen consists of MRG003 (becotatug vedotin), an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR); tislelizumab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; and capecitabine, an oral fluoropyrimidine carbamate. MRG003 delivers the microtubule-disrupting agent monomethyl auristatin E (MMAE) directly to EGFR-expressing tumor cells. Tislelizumab acts as a checkpoint inhibitor to restore T-cell anti-tumor activity. Capecitabine is converted to 5-fluorouracil in the body, where it inhibits thymidylate synthase to interfere with DNA synthesis. This specific treatment protocol, involving an induction phase followed by maintenance therapy, is currently in Phase 2 clinical trials led by Fujian Cancer Hospital.
- Brand names
- TevimbraXeloda
- Other names
- becotatug vedotin + tislelizumab + capecitabine
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on MRG003 + tislelizumab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRG003 + tislelizumab + capecitabine.